A $4.57 share price discounts much of Vanda's commercial execution risk, but the apparent $170m liquidity cushion is shrinking rapidly. Fanapt grows while HETLIOZ erodes, and NEREUS/BYSANTI have yet to prove sustained demand. Our $8.38 base value implies 83.4% upside, conditional on an expense reset and an achievable launch ramp; a failed ramp can erase the gap and force financing.
Methodology. Current enterprise value is estimated from a discounted forward sales multiple. Expected operating losses are reflected in that multiple, while June balance-sheet liquidity is added once. Product-specific rNPVs deduct their own future development and launch costs. The 2.6% modeled share expansion handles modest dilution. The probabilities describe scenarios rather than an additional weighted-average value. The 2024 Future Pak proposal is neither a current bid nor a price floor. Not investment advice.
| Component | Assumption | USD/share |
|---|---|---|
| Commercial portfolio EV | $290m 2027E sales x 1.10x forward EV/sales; includes the existing-label Fanapt, BYSANTI, HETLIOZ, PONVORY and NEREUS franchises. The 44% peer discount reflects generic erosion, cash burn and launch risk; no separate expected-burn deduction. | +5.28 |
| June 2026 net cash | $170.03m cash and marketable securities less $22.83m lease liabilities; divided by 60.455m current shares. | +2.43 |
| Quimilza US GPP rNPV | 65% probability x ~$61.5m after-royalty and after-launch-cost NPV = ~$40m; EU assigned zero in base. | +0.66 |
| HETLIOZ DSWPD rNPV | 70% probability x ~$20m incremental NPV = ~$14m; existing HETLIOZ sales are already in commercial EV. | +0.23 |
| Prospective dilution | 2.6% additional shares to ~62.05m over the valuation horizon, in line with a modest continuation of historical share growth; dilution adjustment to current-share value. | -0.22 |
| Base fair value | Sum of displayed per-share values; ~$520m pre-dilution equity / ~62.05m modeled shares. | $8.38 |
June 30 liquidity $55.9m cash + $114.1m marketable securities. StockAnalysis classifies $22.8m lease liabilities as debt; net liquidity $147.2m after that deduction. No conventional term loan identified in the 10-Q. Shares × T-1 close = ~$276.3m equity value. 52-week range $4.27–$9.94; $4.57 falls within it.
| USD millions | FY2023 | FY2024 | FY2025 | H1 2026 | FY2026 guidance |
|---|---|---|---|---|---|
| Net product sales | 192.6 | 198.8 | 216.1 | 102.2 | 240–290 |
| Fanapt sales | 90.9 | 94.3 | 117.3 | 65.5 | Included with BYSANTI 150–170 |
| HETLIOZ sales | 100.2 | 76.7 | 71.4 | 21.5 | Included in other 80–90 |
| PONVORY sales | 1.6 | 27.8 | 27.4 | 14.1 | Included in other 80–90 |
| NEREUS sales | — | — | — | 1.0 | 10–30 |
| GAAP net loss | See 10-K | -18.9 | -220.5 | -111.1 | Not guided |
| Operating cash flow | See 10-K | -15.8 | -109.4 | -81.3 | Not guided |
FY2025 net loss includes a one-time $113.7m noncash deferred-tax valuation allowance. Even excluding it, the adjusted net loss was $106.8m. The H1 2026 operating cash outflow of $81.3m is a better near-term liquidity signal than the tax-distorted FY2025 GAAP loss.
| Quarterly, USD m | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 |
|---|---|---|---|---|---|
| Revenue | 52.6 | 56.3 | 57.2 | 51.7 | 50.5 |
| GAAP net loss | -27.2 | -22.6 | -141.2* | -48.6 | -62.5 |
| Cash + securities, period end | See Q2 10-Q | 293.8 | 263.8 | 202.3 | 170.0 |
*Q4 2025 includes the $113.7m noncash tax allowance. Q4 revenue = FY2025 less nine-month revenue. Q3 net loss rounded from the 2025 Q3 filing. Q2 2025 liquidity is omitted here to avoid inferring a number from stale data.
H1 2026 operating cash use was $81.3m: $50.2m in Q1 and $31.1m in Q2. The H1-average straight-line stress implies ~4.2 quarters of gross June liquidity, while management projects funding through at least end-2027 on improving sales and lower spending. Our 1.10x multiple already prices expected burn and launch uncertainty; there is no second $105m deduction. An unexpected $50m liquidity gap would reduce value by about $0.81 per modeled share; an illustrative $75m equity raise at $4.57 would add ~16.4m shares (~27% of the current count), materially lowering per-share value. No formal raise has been announced.
Products, pipeline and market structure
Fanapt + BYSANTI 2025 $117.3m Fanapt; 2026 guide $150–170m combined Ramping Psychiatry. Fanapt Q2 rose 23% to $36.0m. BYSANTI was FDA-approved for bipolar I/schizophrenia but its expected H2 launch can cannibalize Fanapt. Model both as one franchise, at >90% product gross margin before sales costs. HETLIOZ 2025 $71.4m; H1 2026 $21.5m Generic pressure Circadian product. Q2 sales -66% YoY to $5.6m, partly affected by ~$7m orders shipped at quarter end but recognized in Q3. DSWPD label expansion is modeled separately as incremental rNPV, not existing sales. PONVORY 2025 $27.4m; H1 2026 $14.1m Stable niche Oral S1P modulator for relapsing multiple sclerosis. Q2 $7.9m (+12%). Competitive, high gross margin, but specialty distribution and commercial spend matter. NEREUS Q2 2026 $1.0m; 2026 guide $10–30m Early launch NK1 antagonist for prevention of motion-induced vomiting. May launch included DTC. Initial wholesale stocking makes demand uncertain; GLP-1 vomiting is a separate Phase III option excluded from base FV.
Pipeline and standard of care. Quimilza (imsidolimab) blocks IL-36 receptor in generalized pustular psoriasis. Approved Spevigo (spesolimab) is the important competing IL-36R therapy; imsidolimab therefore needs differentiated access, pricing or dosing. GEMINI-1: clear/almost-clear skin at week 4 in 8/15 at either imsidolimab dose versus 2/15 on placebo (p=0.023 in each comparison). The trial is small; safety and long-term maintenance remain relevant. GEMINI-2 studied repeat subcutaneous dosing. FDA BLA review targets 2026-12-12. EU orphan status supports development but is not marketing authorization. HETLIOZ DSWPD Phase III: 37.1-minute placebo-adjusted sleep-onset shift (p=0.022), 40 patients in the analysis; no new 28-day safety signal, but the company has yet to file an sNDA. VQW-765 social anxiety and NEREUS GLP-1 vomiting readouts remain unpriced upside until reproducible results.
| Asset / geography | Stage / evidence | Base POS | Unrisked NPV | Risked value |
|---|---|---|---|---|
| Quimilza / US GPP | BLA; Dec 12, 2026 action date; GEMINI-1 n=45 | 65% | $61.5m net of royalties, launch costs and tax | $40m |
| Quimilza / EU GPP | Orphan designation; no filed marketing application | 20% | Not robustly estimable | $0 base; bull only |
| HETLIOZ / US DSWPD | Positive Phase III; sNDA intended | 70% | $20m incremental | $14m |
| VQW-765 / US social anxiety | Phase III pending | 35% | Not robustly estimable | $0 base; bull only |
| NEREUS / US GLP-1 vomiting | Phase III pending | 35% | Not robustly estimable | $0 base; bull only |
Incremental rNPV mechanics: Quimilza assumes illustrative US cash contribution of $20m yearly in 2028-2035 (roughly $60m peak revenue at a one-third net contribution), discounted 18% and reduced by about $8m remaining launch commitments to ~$61m before 65% POS. DSWPD assumes ~$8.3m incremental annual cash contribution in 2028-2032, discounted 18%, less ~$2m filing and launch cost to ~$20m before 70% POS. These are model assumptions, not company guidance. POS build-up is analyst judgment: Quimilza starts at 75% after pivotal efficacy, less 10 points for small trials, competitor and CMC/label uncertainty; HETLIOZ starts at 80% for an already approved active drug, less 10 points for the 40-patient dataset and generic economics. Product-specific rNPVs are incremental to the 2027 commercial sales EV; failed approvals are assigned zero. Peak sales, exclusivity and royalty details remain uncertain, so the rNPVs are deliberately capped.
Risk grid
SWOT
- +Five FDA-approved commercial products
- +Fanapt prescription growth
- +High product gross margin
- +No conventional funded debt; liquid securities
- −$81.3m H1 operating cash use
- −HETLIOZ generic contraction
- −Early NEREUS sales include channel uncertainty
- −Profitability depends on expense reset
- →Quimilza GPP approval and launch
- →DSWPD HETLIOZ label expansion
- →BYSANTI psychiatry adoption
- →Potential GLP-1 vomiting indication
- !Spevigo competition
- !FDA delay or restrictive Quimilza label
- !Dilution if burn persists
- !Payer pressure and product cannibalization
Investment summary
- Fanapt Q2 sales +23% and prescription growth support psychiatry franchise.
- Positive DSWPD Phase III and Quimilza FDA review create identifiable catalysts.
- 2026 guidance requires H2 sales $138–188m after H1 $102m.
- Cash use must slow while NEREUS and BYSANTI show patient-level demand.
- Unexpected ~$50m liquidity shortfall removes ~$0.81 per modeled share.
- Quimilza delay plus stalled launch can place equity below $4.57.
Sources and timestamps. Vanda Q2 2026 10-Q ; Q2 results and guidance ; 2025 10-K ; GEMINI clinical study ; DSWPD Phase III release ; VNDA dated price ; second historical price check ; VNDA market statistics ; SUPN , HRMY , AMPH peer statistics; dated short interest ; dated analyst targets . MARKET_DATA_AS_OF_DATE: 2026-10-09; VNDA close $4.57, implied market cap ~$276.3m, 52-week $4.27–$9.94, shares 60.455m. Financial statements to 2026-06-30; clinical update to 2026-09-29. Estimates are author calculations as of 2026-10-12. ⚠️ Not investment advice.